𝔖 Bobbio Scriptorium

✦ LIBER ✦

71 Effect of genotype and other baseline factors on response to peginterferon α-2a (40 kDa) (PEGASYS®) in HBeAg-positive chronic hepatitis B: Results from a large, randomised study

Book ID: 117373583
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 239 KB
Volume: 42
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)81483-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

512 Sustained response to peginterferon

512 Sustained response to peginterferon α-2a (40 kDa) (PEGASYS®) in HBeAg-negative chronic hepatitis B. 1-year follow-up data from a large, randomised multinational study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 257 KB

523 Effect of ALT flares on efficacy and

523 Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (PEGASYS®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 253 KB

40 kDa peginterferon alfa-2A (PEGASYS®):

40 kDa peginterferon alfa-2A (PEGASYS®): efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B: Graham E Cooksley, Royal Brisbane Hospital, Herston, Queensland Australia; Teerha Piratvisuth, Songklanakarin Hospital, Songkla Thailand; Yuan-Jen Wang, Teipei Veterans General Hospital, Taipei Taiwan; Varocha Mahachai, Chulalongkorn Hospital, Bangkok Thailand; You-Chen Chao, Tri Service General Hosptital, Taipei Taiwan; Tawesak Tanwandee, Siriraj Hospital, Bangkok Thailand; Anuchit Chutaputti, Pramongkutklao Hospital, Bangkok Thailand; Wen Yu Chang, Kaohsiung University Hospital, Kaohsiung Taiwan; Friederike E Zahm, Hoffmann-La Roche Basel Switzerland; Nigel Pluck, Roche Products Ltd, Welwyn Uk

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB